Abstract: The precise and conceptual insight of circulating endothelial progenitor cell (EPC) kinetics is hampered by the absence of an assay system capable of evaluating the EPC differentiation cascade. An assay system for EPC colony formation was developed to delineate circulating EPC differentiation. EPC colony-forming assay using semisolid medium and single or bulk CD133 
D espite significant efforts in research and development with respect to endothelial progenitor cell (EPC) biology during the past 10 years after their initial isolation, 1 EPC remain a controversial topic among researchers because there is no definitive delineation of EPC, no clear differentiation hierarchy, or any unambiguously defined isolation protocol.
EPC have been quantified and qualified either as cell populations identified by cell surface markers such as CD34, CD133, vascular endothelial growth factor receptor-2 (VEGFR-2), [1] [2] [3] [4] [5] [6] [7] [8] or as adhesive cells 6, 9, 10 and colonies 11 using conventional EPC culture methods to produce spindle-shape adherent cells from peripheral blood (PB), bone marrow (BM), or umbilical cord blood (UCB) mononuclear cells (MNC) with endothelial growth factors and cytokines. These assays using conventional EPC culture protocols were simple and satisfactory to speculate on the vasculogenic properties of EPC-enriched fractions but have recently been criticized. These assays further group heterogeneous EPC into one qualitative category: "adhesive cultured EPC" without any hierarchical discrimination and proper characterization of contaminating cell populations, consisting mainly of hematopoietic cells. 12, 13 Later, Ingram and Yoder et al demonstrated endothelial differential stages, high-proliferative-potential endothelial colonyforming cells (ECFC) and low-proliferative-potential ECFC and, using their original culture parameters, demonstrated clonal colony-forming units (CFU) in outgrowth EPC, cultured adhesive EPC, or differentiated endothelial cells (EC). 14 -16 This carefully conceived culture assay system, demonstrating thorough insight into stem cell biology, contributes significantly to the development of EPC biology via the introduction of a differential hierarchy system for EC. It, however, does not likely address the identification of primary circulating EPC from PB, BM, or UCB, but rather the isolation of CFU from cultured adhesive cells of tissuederived EC or EPC (Supplemental Figure I available online at http://www.circresaha.org).
Considering the necessity to create a defined assay to detect EPC qualitatively and quantitatively from primary blood samples, we have developed a new colony assay system. Our method utilizes the conventional methylcellulose assay for stem/progenitor cell identification and is modified to resemble the previously developed semisolid colony assay system for the determination of EPC-CFU. [17] [18] [19] The advantage of this semisolid colony assay lies in its ability to estimate the number of immature progenitors, which will go on to form colony units from a single cell, and its possibility to assess the differential quality of colonies without any contamination of differentiated cells. Furthermore, we devised a semisolid media condition capable of evaluating the adhesive potential of endothelial lineage colonies. We performed EPC colony-forming assay (CFA) similar to the one described here using c-Kit ϩ /Sca-1 ϩ /lineage-negative cells as a murine EPC-enriched population and identified two distinct colony types (small and large colonies) that likely represent two distinct EPC populations, primitive (small) and definitive (large) EPC, respectively. 20 -23 By taking the useful aspects of these former animal studies, we have established a novel adhesive clonogenic assay system for the quantitative and qualitative analysis of human EPC based on the EPC differentiation hierarchy. The methodological concepts of EPC biology were examined using EPC-CFU analysis of single cells or bulk cells from EPCenriched arbitrary fractions or nonselected populations and cell fate analysis of single cells or bulk cells after suspension conditions. Our newly introduced analytic system clarifies the cell fate of each sample cell, reviews the differentiation hierarchy of EPC, and identifies the determinants of EPC proliferation, commitment, and differentiation in vitro and in vivo.
Materials and Methods
Methods for each assay or analysis described are detailed in the Supplemental Materials (available online at http://www.circresaha.org): (1) preparation of MNC and CD133 ϩ cells from UCB, PB, PB with granulocyte-colony stimulating factor mobilization (mPB), or BM; (2) protocol for EPC-CFA, bulk cell expansion (EX) culture of UCB-133, and EPC culture assay; (3) endothelial characterization of EPC-CFU by fluorescent staining; (4) harvest of colony cells from EPC-CFU; (5) FACS analysis; (6) real-time polymerase chain reaction for quantification of endothelial marker gene expression of colony cells derived from single cells of UCB-133; (7) in vitro vasculogenic assay of colony cells; (8) in vivo vasculogenic assay of colony cells in murine ischemic hind limb model; (9) single-cellbased hemato-endothelial lineage commitment assay of UCB-133, mPB-133, and BM-133; and (10) statistical analysis.
Results

Identification of Single-Cell-Derived EPC Colonies
To evaluate and qualify single-cell-derived human EPC colonies, we used single cells from UCB-133 that were sorted into individual wells of a 96-well plate ( Figure 1A ). Among 60 single cells per UCB from 19 different UCB samples (1140 single cells in total), certain single UCB-133 cells developed adherent cell colonies ( Figure 1B) . At day 18 after plating of single UCB-133 cells, two types of colonies could be defined via light microscopy. The first type consisted of small EPC with a diameter of Ϸ10 m to 20 m. The second type consisted of large EPC with a longitudinal length of Ϸ50 m to 200 m, forming mainly a monolayer structure ( Figure 1B) . We termed the former colony a small EPC-CFU and the latter a large EPC-CFU.
Both colonies took up acetylated low-density lipoprotein conjugated 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate and were positive for Ulex europaeus agglutinin I conjugated FITC binding, which characterizes endothelial and monocyte lineages ( Figure 1B ). The expressions of the endothelial-specific genes VEGFR-2, vascular endothelial cadherin, endothelial nitric oxide synthase, endothelial-specific receptor tyrosine kinase, von Willebrand factor, and platelet/EC adhesion molecule (CD31) were detected by quantitative reverse-transcriptase polymerase chain reaction for both analyzed colony types, with large EPC-CFU showing overall higher expression levels (Figure 1C) . Both colony types also expressed leukocyte/monocyte lineage marker genes CD45 and CD14, with large EPC-CFU showing lower levels of expression when compared to small EPC-CFU.
The average frequencies of small EPC-CFU and large EPC-CFU were 16.8%Ϯ1.8% and 5.2%Ϯ1.0% out of single UCB-133 cells, respectively. No single UCB-133 cell producing both types of EPC colonies was detected ( Figure 1C ). To investigate the relationship between small EPC-CFU and large EPC-CFU with regard to their differentiation hierarchy, the cells harvested from small EPC-CFU (small EPC) in primary CFA were reseeded and subsequently revealed large EPC-CFU in secondary CFA after 10 days ( Figure 1D ). This was also confirmed via cell size transition from small to large in the forward scatter plot using FACS analysis ( Figure 1D ).
Non-standard Abbreviations and Acronyms
Single-cell EPC-CFA of CD133 ϩ cells revealed differences in the overall EPC commitment frequency between the analyzed samples, with mPB showing higher frequencies of EPC colonies than BM-derived samples (Supplemental Figure II available online at http://www.circresaha.org), albeit the distribution of each EPC-CFU type remained the same. Our findings indicate that single-cell EPC-CFA enables the 
Characterization of EPC-CFU
After proving that we could generate cells of the endothelial lineage from a single cell, we further developed the methodology to quantify and qualify EPC-CFU from bulk cell populations using MNC and primary or EX-cultured CD133 ϩ cells isolated from UCB (UCB-MNC, UCB-133, and UCB-133EX, respectively) (Figure 2A, B) . At day 18 after plating of UCB-MNC, UCB-133, or UCB-133EX cells, the features and numbers of adherent colonies were examined via light microscopy.
As observed in single-cell EPC-CFA, two types of colonies, small EPC-CFU and large EPC-CFU, were identified and quantified ( Figure 2C ). Examination of the forward scatter and side scatter patterns obtained by FACS analysis of respective colony cells harvested from small EPC-CFU and large EPC-CFU (small EPC and large EPC) revealed distinct differences. Small EPC harvested from primary EPC-CFA converted their morphological features to large EPC in a secondary EPC-CFA. However, large EPC from primary EPC-CFA retained their morphology. When harvesting small EPC, the frequency of small cells in UCB-133 was predominantly higher than in UCB-133EX. However, when large EPC were selectively harvested, the large cell number compared to the small cell number was enriched, especially for UCB-133EX, with the latter originally showing a higher frequency in UCB-133 ( Figure 2C ).
Furthermore, in the secondary EPC-CFA of small EPC, the small cell number decreased and inversely the large cell number increased. In the secondary EPC-CFA of large EPC using UCB-133 or UCB-133EX, the ratio between small and large cell numbers remained similar to the number obtained in the primary EPC-CFA.
To elucidate the different ratios between the two types of colonies, we performed secondary EPC-CFA of both small EPC and large EPC from UCB-133 or UCB-133EX, reseed- ing the cells at escalating low cellular densities (Supplemental Figure III , Supplemental Table I , available online at http://www.circresaha.org). These findings allow the conclusion that small EPC can functionally differentiate into large EPC, indicating the presence of a differentiation hierarchy between both cell and corresponding colony types.
When examining EPC-CFA from UCB-133EX, both colony types took up acetylated low-density lipoprotein conjugated 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindo-carbocyanine perchlorate, were positive for Ulex europaeus agglutinin I conjugated FITC binding, and could be stained with specific antibodies against the endothelial markers VEGFR-2, endothelial nitric oxide synthase, and vascular endothelial cadherin ( Figure 2D ).
To discriminate the differential phenotype between small EPC-CFU and large EPC-CFU, functional assays examining EPC in vitro and in vivo were performed. Regarding the cell cycle status of the respective colonies, small EPC revealed high proliferative activity as compared to large EPC in the applied BrdUrd uptake assay. In UCB-133EX, the percentage of small EPC in the S-phase was 11.3%Ϯ0.2% (R2), whereas this value for large EPC was only 2.2%Ϯ0.3% (R5), as shown by FACS analysis with BrdUrd-FITC and 7-amino-actinomycin D ( Figure 3A) .
By day 18 in semisolid culture with 500 EX-cultured cells per dish, the cell number of small EPC per colony (44.7Ϯ5.4ϫ10
3 ) was 9.6-fold higher than that of large EPC (4.7Ϯ0.4ϫ10 3 ; Figure 3A ). Similar results were also ob- tained for UCB-133 samples, as shown in Supplemental Figure IV (available online at http://www.circresaha.org). These findings suggest that small EPC possess a higher proliferative activity than large EPC. In addition, the vasculogenic activities of the two colony types were evaluated using adhesion, sprouting, and tube formation assays. In adhesion assay, large EPC demonstrated 1.6-fold higher adhesive potential than small EPC (16.5Ϯ1.0/ ϫ10 high-power field [HPF] for small EPC vs 26.1Ϯ1.0/ϫ10 HPF for large EPC; Figure 3B ).
Tube formation assay using either type of colony cells cocultured with human umbilical vein EC demonstrated that large EPC promoted significantly more tube formation at an approximate rate of 1.3-fold, along with a higher incorporation rate into tube-like structures at 16-fold compared to small EPC ( Figure 3C ). EPC Matrigel culture assay revealed the intensive sprouting activity of large EPC at 8.5-fold compared to small EPC (2.2Ϯ0.4/ϫ10 HPF for small EPC vs 18.6Ϯ1.5/ϫ10 HPF for large EPC; Figure 3D ). These findings suggest that colonized large EPC may contribute more actively to neovascular formation by direct incorporation into vascular structures.
The functional activity of each colony-forming EPC was assessed by an in vivo neovascularization assay using a murine hind limb ischemic model. The transplantation of large EPC augmented the capillary density two-fold compared to the control media group and 1.5-fold compared to small EPC administration ( Figure 4A ). Laser Doppler measurement demonstrated large EPC improved blood perfusion in ischemic hind limbs compared with media controls at 3 to 4 weeks, whereas small EPC did not significantly improve perfusion until 4 weeks ( Figure 4B ). Limb salvage recovery could be observed more frequently in the large EPC than the small EPC transplantation group ( Figure 4C ).
Gene expression analysis using human-specific primers 2 days after EPC transplantation revealed that Ki67 is predominantly expressed in small EPC transplants. The expression of VEGF was increased in the small EPC transplanted samples, with large EPC showing an increase in the expression of the proangiogenic growth factor PlGF. Thymosin ␤4 was expressed at similar levels in both sample types. Endothelial-specific maker expression, including von Willebrand factor, endothelial nitric oxide synthase, and CD31, was higher in large EPC when compared with small EPC ( Figure 4D , Supplemental Figure V , available online at http://www.circresaha.org).
By immunohistochemistry, small EPC were preferentially found to be close to but outside of host capillaries (Supplemental Figure VIA available online at http://www.circresaha.org) and thus appeared to be involved in an indirect interaction with host EC leading to cooperative neovascular formation (Supplemental Figure VIB) . However, large EPC were frequently found in close proximity to and rarely outside of the host vasculature possibly mediating direct cooperative vasculogenesis (Supplemental Figure VIC and D, Supplemental Video, available online at http://www.circresaha.org).
As also indicated by the results summarized in Figure 3C , small EPC may assert their proangiogenic properties via supporting paracrine effects, whereas large EPC may be characterized by their ability to contribute directly to vascular structure formation during postnatal vasculogenesis. Taken together, these findings indicate that there are at least two kinds of CFU of EPC, small EPC-CFU and large EPC-CFU. Small EPC are proliferative and likely immature, whereas large EPC are more differentiated and have greater vasculogenic potential.
Methodological Development of an EPC-CFA for Bulk Cell Samples
To verify the methodological reliability of the herein described EPC-CFA, colony-forming abilities of primary (UCB-133) and cultured (UCB-133EX) samples were further evaluated and compared. As demonstrated in Figure 5A and Supplemental Table II (available online at http://www.circresaha.org), UCB-133 developed predominantly small EPC-CFU (19.3Ϯ1.17 in UCB-133 vs 6.6Ϯ1.04 in UCB-133EX), whereas UCB-133EX inversely promoted the formation of large EPC-CFU rather than small EPC-CFU (12.4Ϯ2.15 in UCB-133EX vs 6.0Ϯ1.13 in UCB-133), with the total CFU number staying similar between UCB-133 and UCB-133EX.
The CFU number count of EX-cultured cells revealed an expansion of both small EPC-and large EPC-CFU, forming cell types during the conditioning period (20.2-times and 100.6-times, respectively). These findings indicate that the described EPC-CFA not only enables the detection of differential phenotype changes between CFU but also allows the measurement of the expansion range as well as colony bioactivity for each CFU forming cell population during EX-culture from UCB-133 to UCB-133EX.
To verify the accuracy of our applied EPC-CFA and to optimize the cell number necessary for proper evaluation, CD133 ϩ cells and MNC isolated from PB, mPB, BM, or UCB were examined dose-dependently ( Figure 5B , Online Table III , available online at http://www.circresaha.org). The colony numbers obtained in EPC-CFA revealed cell dose-dependent occurrence of colonies for each sample, despite a saturation effect when the total colony number exceeded 30 in a 35-mm dish. Further, the colony number of each sample was evaluated by optimizing a cell dose that resulted in an average colony number of 15 to 30.
Of note, in BM-MNC and mesenchymal and stromal cells started growing at Ϸ2 weeks after culture, interfering with EPC colony formation, indicating that BM-MNC as a cell source is not applicable to EPC-CFA (Supplemental Figure VII available online at http://www.circresaha.org), despite the fact that EPC-CFU could still be observed. There are also slight differences in the colony phenotype ratio for small EPC-CFU and large EPC-CFU between MNC and CD133 ϩ cells for each analyzed tissue or among the applied cellular doses within a cell type ( Figure 5C ). We speculate that these differences may be attributable to alterations in the level and type of secreted growth factors by selected vs nonselected cell populations. The aforementioned results suggest that our EPC-CFA is precise and representative in various sample measurements and can even be used to evaluate nonselected samples when the methodology is properly optimized. Interestingly, the average square area unit values of each EPC-CFU derived from UCB-MNC or UCB-133 cells were significantly higher than the values found for the other analyzed tissue types (PB, BM), indicating superior colony formation potential of UCB-derived EPC ( Figure 5D 
Evaluation of Growth Factor-Mediated Signaling for EPC Development
To demonstrate the significance of the described EPC-CFA and its potential use in EPC biology, the effect of VEGF was examined using our single-cell culture conditions. Furthermore, EPC-CFA was evaluated along with and combined with a hematopoietic progenitor cell (HPC)-CFA to determine the endothelial and hematopoietic differentiation capability of a single stem cell in a hemato-endothelial lineage commitment assay.
A total of 720 single cells (60 cells/group/UCBϫ6UCB samples) sorted from UCB-133 into each well of 96-well plates were cultured for 7 days in EX-culture medium, supplemented with rh-TPO, rh-SCF, rh-IL6, and rh-Flt-3 ligand, with or without rh-VEGF ( Figure 6A, B) . EX-culture media allowed single UCB-133 cells to attain similar total cell numbers irrespective of VEGF supplementation ( Figure  6C ). Although 32% of single UCB-133 cells from both groups did not grow, 68% of UCB-133 cells increased in number to an average rate of Ϸ120 cells over 7 days, irrespective of VEGF supplementation ( Figure 6C ). After these culture conditions, half of the single-cell-derived expanded cells in each well were applied to EPC-CFA and the other half were applied to HPC-CFA, respectively. Among the single-cell-derived cells cultured without VEGF, the frequency of colony development was 0.4%Ϯ0.4% for EPC only, 25.4%Ϯ3.8% for HPC only, and 24.2%Ϯ2.8% for EPC plus HPC. However, after conditioning with VEGF, the frequency of EPC only and EPC plus HPC increased (1.7%Ϯ1.4% and 36.3%Ϯ3.4%, respectively), whereas the frequency for HPC only decreased (11.7%Ϯ3.3%; Figure 6D ). Notably, VEGF increased the cellular commitment to large EPC-CFU but not small EPC-CFU or mixed (small and large) EPC-CFU ( Figure  6D ). Correlative analysis between the cells forming EPC colo- nies and HPC colonies represented an antagonistic decrease in pro-HPC expanding populations when conditioned with VEGF ( Figure 6D ).
These single-cell culture results indicated the presence of populations that can give rise to both endothelial and hematopoietic progenitors in vitro at a ratio of Ϸ24% without VEGF or 36% with VEGF. Furthermore, it demonstrated that VEGF enhanced EPC differentiation and interfered with HPC differentiation. Our EPC-CFA thus can function as a suitable assay to define and test factors and signaling molecules (Supplemental Figure XA , B available online at http://www.circresaha.org) possibly involved in EPC proliferation, commitment, and differentiation. The hemato-endothelial lineage commitment assay was also effectively used to analyze the differences in hematoendothelial lineage commitment among different hematopoietic cell sources (Supplemental Figure XIA , B, available online at http://www.circresaha.org).
Comparison of EPC-CFA With Conventional EPC Culture Assay
We compared and analyzed the relationship of EPC-CFU in EPC-CFA with early EPC, the equivalent phenotype of EC-like cells, circulating angiogenic cells, or CFU-EC detected in conventional EPC culture assay. First, we evaluated the differences in the cell populations giving rise to the aforementioned cells or colonies. Cells isolated from UCB-MNC using antibodies against CD14 and CD133 were examined by EPC-CFA and EPC culture assay. As shown in Supplemental Figure XII (available online at http://www.circresaha.org), there was almost no double positivity of CD133 and CD14 in UCB-MNC. Early EPC were produced only from CD14 ϩ /CD133
in EPC culture assay. Conversely, the CD14 Ϫ /CD133 ϩ (CD133 ϩ ) fraction produced small and large EPC-CFU in EPC-CFA, and the other fractions did not. These findings correspond to the reports by Rhode et al, 24 in which cultured CD14 ϩ fractions produce EC-like cells as early EPC, and CFU-EC are formed of CD14 ϩ cells derived from circulating angiogenic cells aggregating with CD14 Ϫ cells in culture.
We further followed the changes in positivity of CD133/ CD14 in small EPC-CFU cells (described in Supplemental Methods available online at http://www.circresaha.org) during the period of EPC-CFA. Positivity for CD133 declined exponentially and reached almost zero at day18 of EPC-CFA; inversely, CD14 levels increased dramatically after 7 days and reached their maximum at day 18 (Supplemental Figure XIIIA available online at http://www.circresaha.org). Conventional EPC culture assays using small EPC-CFU cells isolated at the differential time points during EPC-CFA disclosed an increase in early EPC productivity along the applied time course. This finding suggests that differentiating initial CD133 ϩ cells, possible CD14 ϩ cells, in small EPC-CFU may give rise to early EPC (Supplemental Figure XIIIB) .
We then investigated the FACS profiles of subsequent cultured EPC from small EPC at day 18 in EPC-CFA, exhibiting the presence of primary markers labeling both EC and monocyte lineage cells similar to early EPC or circulating angiogenic cells found in EPC culture assays from UCB-MNC (Supplemental In this regard, we define that colony-forming EPC are derived from CD133 ϩ cells and give rise to small EPC-CFU and large EPC-CFU, whereas noncolony-forming EPC express CD14 ϩ and have an early EPC phenotype. These findings indicate that the EPC colony-forming potential declines along with the decrease in CD133 positivity, whereas inversely the producing activity of early EPC augments along with the increase in CD14 positivity because of the progress of EPC differentiation from CD133 ϩ cells in EPC-CFA. In this regard, an early EPC arising during EPC culture assay likely reflects a differentiating phenotype of an EPC-CFU cell, which it derives from, and thus is not likely related to, the original cell population giving rise to EPC-CFU.
Discussion
Establishment of a Novel Clonogenic Assay System for Immature EPC
The study of EPC has been obscured by the lack of an authoritative and clear definition of EPC. This, in turn, was caused by the lack of a proper and unambiguous EPC assay. Among the EPC assays used over the years, the most reliable assay was the colony assay for endothelial outgrowth cell (EOC) culture, developed by Ingram and Yoder 15 (Supplemental Figure I) . The EOC assay demonstrated adhesive endothelial potential at different stages, high-proliferative-potential ECFC and low-proliferative-potential ECFC, revealing clonal CFU in outgrowth EPC, cultured adhesive EPC, or differentiated EC. The EOC is convenient for basic research applications because of its stable profile and reproducibility. However, it does not likely relate to the identification of a primary EPC phenotype from PB, BM, or UCB, but rather to the isolation of CFU from cultured attached cells, which in turn are based on tissue-derived EC or EPC.
In this regard, we have established a novel clonogenic assay system for the quantitative and qualitative analysis of primary EPC of the endothelial lineage (Supplemental Figure I) . First, the assay was designed to identify EPC-CFU from single cells. After the described isolation and culture conditions, we succeeded in the generation and characterization of EPC colonies from single UCB-133 cells. Furthermore, EPC-CFU could be detected not only from single cells but also from bulk cells of EPC-enriched populations (ie, CD34 ϩ or CD133 ϩ cells), arbitrary fractions (ie, lineage-negative cells), or nonselected populations (ie, total MNC of PB, or UCB). The capability to measure the EPC-CFU number from bulk cells opens the practical opportunity to quantify reproducibly EPC-CFU from experimental and clinical samples using this assay system. As mentioned, many laboratories have tried conventional EPC assays for clinical samples and basic research but found them to be rather incomplete and insufficient for a fundamental and proper quantification and qualification of EPC. In this respect, the methodological applicability and usefulness of the introduced assay could be further proven by its capability for dose-dependent CFU isolation using dose-escalated cell samples of total MNC form PB and UCB.
Two Types of EPC-CFU
Most importantly, using our described approach, two different types of EPC-CFU derived from a single CD133 ϩ cell could be identified, termed small EPC and large EPC, respectively ( Figure 7 ). These progenitor cell-derived populations can form colonies, which are positive for endothelial markers such as VEGFR-2, endothelial nitric oxide synthase, vascular endothelial cadherin, von Willebrand factor, endothelial-specific receptor tyrosine kinase, and CD31. Small EPC reveal a predominant potential for proliferation, showing an overall higher frequency of the S-phase cell-cycle state. Small EPC also give rise to secondary large EPC colonies when reseeded. Large EPC demonstrate a predominantly vasculogenic potential including cell adhesion and tube-like structure formation in vitro, as well as a high in vivo activity toward de novo blood vessel formation after transplantation into a murine ischemic hind limb model, as compared to small EPC. Large EPC did not form secondary colonies but gave rise to isolated endothelial lineage cells when reseeded. Given these findings, small EPC colony-forming cells can be seen as "primitive EPC," which are possibly derived from further immature and proliferative EPC, and large EPC colony-forming cells can be seen as "definitive-EPC," which are more prone to differentiate and promote EPC-mediated cell functions required for vasculogenesis ( Figure 7 , Supplemental Table V available online at http://www.circresaha.org).
The definitive large EPC are capable to differentiate into a noncolonizing large EPC phenotype, similar to early EPC or circulating angiogenic cells derived via conventional EPC culture [25] [26] [27] [28] and are speculated to represent further differentiated EPC. Approximately 6% of primitive small EPC colony-forming cells and 3% of definitive large EPC colonyforming cells among enriched UCB-EPC populations (UCB-34 or UCB-133) could be observed, whereas only 0.048% of primitive small EPC colony-forming cells and 0.042% of definitive large EPC colony-forming cells among nonenriched UCB-MNC were detected. Being able to detect these two distinct types of EPC enables us to realize our initial objective of a precise and unbiased quantification and qualification of circulating EPC from clinical and biological samples.
HSC-Derived EPC and HPC
Based on the evidence that hematopoietic stem cells (HSC) and EPC 29, 30 are derived from a common precursor (hemangioblast) during embryogenesis, 31,32 the existence of a hemangioblast in the adult has been suggested using in vitro single-cell culture systems utilizing common surface markers shared between EPC and HSC, such as CD34, VEGFR-2, or CD133, as shown for human PB-CD133 ϩ or UCB-CD34 ϩ / VEGFR-2 ϩ and BM-CD34 ϩ /VEGFR-2 ϩ subsets. [3] [4] [5] [33] [34] [35] [36] However, the specific isolation of a postnatal hemangioblast and the characterization of its origin and biological properties have not been successful thus far. In this article, we have demonstrated that our newly introduced EPC-CFA, in combination with an HPC-CFA, allows for further insights into the origin and properties of hematopoiesis and vasculogenesis in adults. A single UCB-CD133 cell could give rise to simultaneous EPC and HPC colonies at the frequency of 36.3% using specific culture conditions. This finding regarding the frequency of single cells to commit into both EPC and HPC is somewhat surprising. The fact that the majority of the HSC population committed mainly into both HPC and EPC, or HPC alone, but not into EPC alone, indicates that the origin of EPC may be represented by a subset of immature hemangioblastic HSC and that EPC commitment from these cells is closely related to the emergence and formation of HPC. Of note, each CD133
ϩ cell exhibited different colony- forming patterns of no EPC-CFU, only small EPC-CFU, or only large EPC-CFU. These findings suggest that even among a scarce cell population like the one expressing the CD133 surface antigen, heterogeneity regarding the ability of EPC commitment exists. The regulatory link between EPC and HPC needs to be further investigated to be able to generate a complete hierarchy illustrating the origin and emergence of these cells, potentially resulting in novel insights not only for vascular biology but also for the hematopoietic system. ϩ ) cells; EPC colony-forming potential declines along with the decrease in CD133 positivity and, inversely, the producing activity of early EPC augments along with the increase in CD14 during the progress of EPC differentiation from CD133 ϩ stem cells in EPC-CFA; and noncolonyforming EPC derived from EPC-CFU express the equivalent phenotype with early EPC. In this regard, we define that colony-forming EPC are derived from CD133 ϩ cells and give rise to small EPC-CFU and large EPC-CFU, whereas noncolony-forming EPC express CD14 ϩ cells and are identified as early EPC phenotype. These findings indicate that the EPC colony-forming potential declines along with decrease in CD133 positivity, inversely producing activity of early EPC augments along with increase in CD14 during the progress of EPC differentiation from CD133 ϩ stem cells in EPC-CFA.
Colony-Forming and Noncolony-Forming Hematopoietic EPC
These findings also recall that myeloid EPC, suggested by Bailey et al, 43 may be equivalent to the early EPC phenotype derived from EPC-CFU primarily expressing CD45 and CD14, although the relationship between colony-forming EPC and myeloid progenitor cells needs to be clarified. Regarding the relationship of early EPC with EOC, equivalent to ECFC or late EPC, both are considered to be generated from different stem cell fractions as previously reported. 44 Later studies by Case et al 45 46 however, EOC colonies could not be detected from three samples of CD34 cell-depleted or CD133 cell-depleted UCB-MNC, whereas total UCB-MNC did. Although it cannot be conclusively ruled out for the moment, the primary and original phenotypes of EPC-CFU and early EPC seem to differ from EOC.
Quest for Molecular and Signaling Mechanisms in EPC Biology
EPC-CFA, alone or combined with HPC-CFA, encourages the quest for the identification of novel factors and signaling molecules involved in EPC and HSC biology. A single UCB-133 cell developed a cell population that gave rise to both EPC and HPC colonies at a frequency of 36.3% after culture with VEGF and of 24.2% without VEGF. Furthermore, VEGF enhanced EPC commitment with an increase in definitive large EPC-CFU (18.3% vs 7.5%) and enhanced an inhibition in HPC commitment (11.7% vs 25.4%), suggesting that VEGF is a determining factor involved in EPC commitment and is capable of changing the balanced cell fate between EPC and HPC present in immature HSC populations. In this regard, we speculate that the herein described EPC-CFA will function simply and precisely as a valuable assay to detect further determining factors that may regulate EPC and HPC proliferation or commitment, advancing vascular and hematopoietic biology.
Standardization of EPC-CFA
Although our EPC-CFA was demonstrated to be simple and representative, one still needs to carefully examine and consider several points to achieve a proper quantification and qualification of EPC-CFU. First, the cell number to be examined should be standardized before the main test. A saturation effect was achieved when the total colony number exceeded 30 in a 35-mm dish. Therefore, the optimal sample cell number for EPC-CFA needs to be determined and set to an average colony number of 15 to 30. This has to be performed not only for the reflection of the individual variations between biological and clinical samples but also for the simple consideration of the diversity of mutual interactions in mixed cell populations used for analysis. As an example, gross differences in the colony phenotype ratio for small and large EPC-CFU between primary UCB-133 cells and UCB-MNC make such an adjustment indispensable ( Figure 5C ). Furthermore, EPC-CFA worked flawlessly for UCB-MNC and PB-MNC, albeit differences in the optimal cell number between the samples could be observed. The observed variability can be accounted for by the overall sample-specific frequency of EPC-CFU and the alterations in the secretion and presence of certain growth factors in the analyzed mixed cell populations. Taken together, the herein introduced EPC-CFA is precise and representative of a variety of sample measurements and can even be used to evaluate nonselected samples when the methodology is properly optimized.
Potential Use of EPC-CFA in the Clinical Setting
Risk factors for cardiovascular diseases such as diabetes affect endogenous angiogenic cells and EPC, 47, 48 thereby attenuating the efficacy of patient-derived cells for therapeutic purposes. Furthermore, increasing evidence suggests that a decrease in stem cell function might play a primary role in the pathogenesis of multiple diseases. 49 The shortcomings and limitations of the methodologies that were available to assess the presence and properties of EPC in patients limited our understanding of the potential role of EPC in the pathogenesis of diseases and the care of patients. In this regard, it is essential to determine the impact of environmental cues and pathogenic factors on the quantitative and qualitative properties of EPC by further clarifying and improving the current concepts of EPC biology. Our EPC-CFA enables the investigation of EPC-related disease mechanisms using PB or BM samples from patients and further allows the study of the effects of pathological multifactors on EPC and EPC-based disease models in vitro. Being able to properly quantify and characterize EPC with our proposed assay system will help to improve existing strategies and to develop novel therapeutic strategies in the field of cardiovascular disease.
